SUPERNUS PHARMACEUTICALS INC (SUPN) Fundamental Analysis & Valuation

NASDAQ:SUPN • US8684591089

Current stock price

49.91 USD
-0.55 (-1.09%)
At close:
49.91 USD
0 (0%)
After Hours:

This SUPN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. SUPN Profitability Analysis

1.1 Basic Checks

  • SUPN had positive earnings in the past year.
  • SUPN had a positive operating cash flow in the past year.
  • SUPN had positive earnings in 4 of the past 5 years.
  • Of the past 5 years SUPN 4 years had a positive operating cash flow.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • SUPN has a Return On Assets of -1.35%. This is in the better half of the industry: SUPN outperforms 76.17% of its industry peers.
  • SUPN's Return On Equity of -1.82% is fine compared to the rest of the industry. SUPN outperforms 78.76% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 2.87%, SUPN belongs to the top of the industry, outperforming 80.83% of the companies in the same industry.
Industry RankSector Rank
ROA -1.35%
ROE -1.82%
ROIC 2.87%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)N/A
ROIC(5y)N/A
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • With an excellent Operating Margin value of 6.08%, SUPN belongs to the best of the industry, outperforming 80.83% of the companies in the same industry.
  • SUPN has a Gross Margin of 89.91%. This is amongst the best in the industry. SUPN outperforms 92.75% of its industry peers.
  • SUPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.08%
PM (TTM) N/A
GM 89.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5Y-0.06%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SUPN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
  • Compared to 1 year ago, SUPN has more shares outstanding
  • SUPN has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • SUPN has an Altman-Z score of 6.01. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
  • SUPN has a Altman-Z score of 6.01. This is in the better half of the industry: SUPN outperforms 79.79% of its industry peers.
  • There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.01
ROIC/WACC0.3
WACC9.49%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 1.80 indicates that SUPN should not have too much problems paying its short term obligations.
  • SUPN has a Current ratio of 1.80. This is in the lower half of the industry: SUPN underperforms 64.25% of its industry peers.
  • SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.56, SUPN is doing worse than 60.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.56
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SUPN Growth Analysis

3.1 Past

  • SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.14%, which is quite good.
  • Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 6.21% on average per year.
  • SUPN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.63%.
  • The Revenue has been growing slightly by 6.68% on average over the past years.
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%

3.2 Future

  • Based on estimates for the next years, SUPN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.52% on average per year.
  • The Revenue is expected to grow by 14.29% on average over the next years. This is quite good.
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue Next Year23.63%
Revenue Next 2Y20.6%
Revenue Next 3Y18.23%
Revenue Next 5Y14.29%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. SUPN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 15.65, which indicates a correct valuation of SUPN.
  • SUPN's Price/Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 85.49% of the companies in the same industry.
  • SUPN is valuated rather cheaply when we compare the Price/Earnings ratio to 25.70, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 25.44 indicates a quite expensive valuation of SUPN.
  • SUPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 75.13% of the companies in the same industry.
  • SUPN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.65
Fwd PE 25.44
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • SUPN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SUPN is cheaper than 80.31% of the companies in the same industry.
  • 77.20% of the companies in the same industry are more expensive than SUPN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 40.53
EV/EBITDA 19.62
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • SUPN's earnings are expected to grow with 18.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)2.52
EPS Next 2Y23.69%
EPS Next 3Y18.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SUPN Dividend Analysis

5.1 Amount

  • No dividends for SUPN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUPN Fundamentals: All Metrics, Ratios and Statistics

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (3/13/2026, 8:00:00 PM)

After market: 49.91 0 (0%)

49.91

-0.55 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners104.2%
Inst Owner Change-0.71%
Ins Owners4.26%
Ins Owner Change2.67%
Market Cap2.87B
Revenue(TTM)718.95M
Net Income(TTM)-19.12M
Analysts83.33
Price Target62.56 (25.35%)
Short Float %7.34%
Short Ratio5.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)0%
PT rev (3m)1.38%
EPS NQ rev (1m)-5.56%
EPS NQ rev (3m)32.47%
EPS NY rev (1m)-46.67%
EPS NY rev (3m)-47.45%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)1.27%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE 15.65
Fwd PE 25.44
P/S 4.21
P/FCF 40.53
P/OCF 39.9
P/B 2.73
P/tB 9.34
EV/EBITDA 19.62
EPS(TTM)3.19
EY6.39%
EPS(NY)1.96
Fwd EY3.93%
FCF(TTM)1.23
FCFY2.47%
OCF(TTM)1.25
OCFY2.51%
SpS11.86
BVpS18.27
TBVpS5.34
PEG (NY)N/A
PEG (5Y)2.52
Graham Number36.21
Profitability
Industry RankSector Rank
ROA -1.35%
ROE -1.82%
ROCE 3.81%
ROIC 2.87%
ROICexc 3.87%
ROICexgc 47.85%
OM 6.08%
PM (TTM) N/A
GM 89.91%
FCFM 10.38%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.32%
Cap/Sales 0.16%
Interest Coverage 250
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.56
Altman-Z 6.01
F-Score5
WACC9.49%
ROIC/WACC0.3
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%
Revenue Next Year23.63%
Revenue Next 2Y20.6%
Revenue Next 3Y18.23%
Revenue Next 5Y14.29%
EBIT growth 1Y-47.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.86%
EBIT Next 3Y40.14%
EBIT Next 5Y27.81%
FCF growth 1Y-58.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.34%
OCF growth 3YN/A
OCF growth 5YN/A

SUPERNUS PHARMACEUTICALS INC / SUPN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to SUPN.


What is the valuation status for SUPN stock?

ChartMill assigns a valuation rating of 5 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.


What is the profitability of SUPN stock?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for SUPN stock?

The Earnings per Share (EPS) of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to decline by -38.5% in the next year.